Dissecting motor cortex modulation of nociception during chronic pain

Ended Grant Awarded Last action

Award ID
R00DE031802
Recipient
Awarding agency
Obligated
$470,477

Award facts

Assistance listing
93.121 Oral Diseases and Disorders Research
Completion date
Place of performance
White Plains, NY 10605, USA

Award details come from USAspending.gov.

Description

Abstract
(see instructions): the heavy burden of chronic pain and the opioid epidemic has prompted an urgent, worldwide search for alternative, non-addictive methods of analgesia. One promising alternative is non-invasive electrical or magnetic stimulation of the motor cortex (MC). While MC stimulation (MCS) has repeatedly been found to reduce chronic pain in human subjects and decrease nociceptive behaviors in rodent models, major questions remain about its mechanism of action and how to improve MCS efficacy. Evidence suggests that MCS antinociceptive efficacy increases when the stimulation targets the region in motor cortex that corresponds to the body part from which pain originates (somatotopically matching MCS) and that MCS analgesia requires endogenous opioid activity. Here, I propose to use a rodent model of trigeminal neuropathic pain to elucidate the underlying mechanism of MCS antinociception and to define key MCS features that pain clinicians can use to improve MCS efficacy. To characterize the MCS mechanism, I will 1) quantify the efficacy of somatotopically matched MCS (SSMCS), 2) determine what opioid receptor subtypes are required for MCS antinociception, and 3) identify how endogenous opioids modulate an opioid-sensitive MC descending circuit to the descending pain control pathways during SSMCS. To determine the efficacy of MCS between matched and off-target MCS in two different nerve constriction models, I will use classic behavioral paradigms along with cutting-edge machine learning algorithms to analyze mouse behavioral responses. I will then use complementary pharmacological and genetic mouse lines to determine how SSMCS is impacted by distinct opioid receptor types. To interrogate the combined impact of MC somatotopy and endogenous opioid signaling in MCS analgesia, I will focus on the descending projection from MC to descending pain control regions, rostral ventromedial medulla (RVM) and spinal trigeminal nucleus caudalis (SPVC). I will determine the positions of opioid receptor types and endogenous opioid peptides along this circuit and then assess the impact of SSMCS with and without opioid signaling on neural activity in MC, RVM, and SPVC using cutting-edge high-density electrophysiological techniques. Altogether, this project will determine how MCS modulates nociception through endogenous opioid signaling in somatotopically aligned circuits. The results will provide the first report of neural activity during and after SSMCS at both the target and in an MC output.

Transactions

Action Obligated Date
Amendment $221,478
Amendment $0
Original award $248,999

Quick answers

Who received award R00DE031802?

R00DE031802 was awarded to The Winifred Masterson Burke Medical Research Institute, Inc. by National Institute of Dental and Craniofacial Research (National Institutes of Health) on August 4, 2025.

How much is award R00DE031802 worth?

$470,477 has been obligated on R00DE031802.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award